BioLineRx (BLRX) trades higher before the bell after saying it received regulatory approval to...

|About: BioLineRx Ltd. (BLRX)|By:, SA News Editor

BioLineRx (BLRX) trades higher before the bell after saying it received regulatory approval to commence a Phase IIa trial for its BL-8040 Leukemia drug. The primary endpoints are safety and tolerability. BLRX lost over half its market cap in March after discontinuing a clinical trial for an antipsychotic. Shares +7% premarket.